Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Leukemia, Myeloid, Chronic-Phase 12Leukemia 6Gastrointestinal Stromal Tumors 6Neoplasm Metastasis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Synovitis, Pigmented Villonodular 2Recurrence 2Ovarian Neoplasms 2Hematologic Diseases 2Blast Crisis 2Substance Withdrawal Syndrome 1Peritoneal Neoplasms 1Neoplastic Processes 1Neoplasm, Residual 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 58Cisplatin 32Oxaliplatin 28Fluorouracil 21lenvatinib 19durvalumab 18Capecitabine 17Leucovorin 15tislelizumab 10pembrolizumab 10apatinib 9Floxuridine 8Specimen Handling 7Panitumumab 7Magnetic Resonance Spectroscopy 7Albumin-Bound Paclitaxel 7sintilimab 6pemigatinib 6Radiotherapy 6Irinotecan 6Drug Therapy 6Biopsy 6tremelimumab 5regorafenib 5olaparib 5camrelizumab 5Taxes 5S 1 (combination) 5Nivolumab 5Folfox protocol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cholangiocarcinoma × nilotinib × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡